Opko Health Inc (OPK) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Opko Health Inc stock (OPK) is currently trading at $1.19. Opko Health Inc PS ratio (Price-to-Sales) is 1.42. Analyst consensus price target for OPK is $3.40. WallStSmart rates OPK as Sell.
- OPK PE ratio analysis and historical PE chart
- OPK PS ratio (Price-to-Sales) history and trend
- OPK intrinsic value — DCF, Graham Number, EPV models
- OPK stock price prediction 2025 2026 2027 2028 2029 2030
- OPK fair value vs current price
- OPK insider transactions and insider buying
- Is OPK undervalued or overvalued?
- Opko Health Inc financial analysis — revenue, earnings, cash flow
- OPK Piotroski F-Score and Altman Z-Score
- OPK analyst price target and Smart Rating
Opko Health Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Opko Health Inc (OPK) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book. Concerns around peg ratio and return on equity. Significant fundamental concerns warrant caution or avoidance.
Opko Health Inc (OPK) Key Strengths (2)
Trading below book value, meaning the market prices it less than net assets
Paying $1.42 for every $1 of annual revenue
Supporting Valuation Data
Opko Health Inc (OPK) Areas to Watch (8)
Company is destroying shareholder value
Losing money on operations
Revenue declining -19.20%, a shrinking business
Earnings declining -12.60%, profits shrinking
Company is losing money with a negative profit margin
Very expensive relative to growth, significant premium
Low institutional interest, mostly retail-driven
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Opko Health Inc (OPK) Detailed Analysis Report
Overall Assessment
This company scores 31/100 in our Smart Analysis, earning a F grade. Out of 10 metrics analyzed, 2 register as strengths (avg 9.0/10) while 8 fall into concern territory (avg 1.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, Price/Sales. Valuation metrics including Price/Sales (1.42), Price/Book (0.66) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including PEG Ratio (93.65) suggest expensive pricing. Growth concerns include Revenue Growth at -19.20%, EPS Growth at -12.60%, which may limit upside. Profitability pressure is visible in Return on Equity at -17.10%, Operating Margin at -29.00%, Profit Margin at -37.20%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -17.10% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -19.20% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
OPK Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
OPK's Price-to-Sales ratio of 1.42x sits near its historical average of 1.5x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 10% below its historical high of 1.57x set in Mar 2026, and 0% above its historical low of 1.42x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Opko Health Inc (OPK) · HEALTHCARE › DIAGNOSTICS & RESEARCH
The Big Picture
Opko Health Inc is in a turnaround phase, with management focused on restoring profitability. Revenue reached 607M with 19% decline year-over-year. The company is currently unprofitable, posting a -37.2% profit margin.
Key Findings
Revenue contracted 19% YoY. Worth determining whether this is cyclical or structural.
The company is unprofitable with a -37.2% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Volatility is elevated with a beta of 1.52, so expect amplified moves relative to the broader market.
Sector dynamics: monitor DIAGNOSTICS & RESEARCH industry trends, competitive moves, and regulatory changes that could impact Opko Health Inc.
Bottom Line
Opko Health Inc is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(2 last 3 months)
| Insider | Type | Shares |
|---|---|---|
PAGANELLI, JOHN A Director | Buy | +10,000 |
| Insider | Type | Shares |
|---|---|---|
UPPALURI, SUBBARAO V Director | Buy | +50,000 |
Data sourced from SEC Form 4 filings
Last updated: 8:23:47 AM
About Opko Health Inc(OPK)
NASDAQ
HEALTHCARE
DIAGNOSTICS & RESEARCH
USA
OPKO Health, Inc., a healthcare company, is engaged in the pharmaceutical and diagnostic businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company is headquartered in Miami, Florida.